U. Keppler

760 total citations
8 papers, 579 citations indexed

About

U. Keppler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, U. Keppler has authored 8 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in U. Keppler's work include Lung Cancer Research Studies (5 papers), Neuroendocrine Tumor Research Advances (3 papers) and Brain Metastases and Treatment (2 papers). U. Keppler is often cited by papers focused on Lung Cancer Research Studies (5 papers), Neuroendocrine Tumor Research Advances (3 papers) and Brain Metastases and Treatment (2 papers). U. Keppler collaborates with scholars based in Germany, Austria and Belgium. U. Keppler's co-authors include U. Gatzemeier, Giorgio V. Scagliotti, Hedy L. Kindler, J.L. Breau, Daniel Betticher, James J. Rusthoven, Michael J. Vasconcelles, Howard A. Burris, Robert Pirker and Pascaline Berthet and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

U. Keppler

8 papers receiving 554 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
U. Keppler Germany	6	463	338	112	62	40	8	579
Swee‐Peng Yap Singapore	7	255 0.6×	287 0.8×	100 0.9×	80 1.3×	37 0.9×	9	532
Hidenori Ibata Japan	14	391 0.8×	275 0.8×	61 0.5×	26 0.4×	23 0.6×	29	574
Yasmin Alam Canada	8	206 0.4×	304 0.9×	114 1.0×	86 1.4×	7 0.2×	8	457
D. Tsavdaridis Greece	12	358 0.8×	612 1.8×	109 1.0×	95 1.5×	14 0.3×	27	722
Anna Maria Mosconi Italy	6	404 0.9×	420 1.2×	129 1.2×	31 0.5×	9 0.2×	9	592
Haruhito Kamei Japan	9	465 1.0×	389 1.2×	53 0.5×	53 0.9×	22 0.6×	37	573
Michèle Natale Germany	8	256 0.6×	293 0.9×	86 0.8×	50 0.8×	7 0.2×	25	415
Casely Ago Canada	6	140 0.3×	184 0.5×	63 0.6×	41 0.7×	28 0.7×	6	324
Jindřich Kopecký Czechia	13	168 0.4×	227 0.7×	106 0.9×	34 0.5×	41 1.0×	57	474
A. Chemaissani Germany	9	508 1.1×	464 1.4×	124 1.1×	18 0.3×	14 0.3×	13	650

Countries citing papers authored by U. Keppler

Since Specialization

Citations

This map shows the geographic impact of U. Keppler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Keppler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Keppler more than expected).

Fields of papers citing papers by U. Keppler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Keppler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Keppler. The network helps show where U. Keppler may publish in the future.

Co-authorship network of co-authors of U. Keppler

This figure shows the co-authorship network connecting the top 25 collaborators of U. Keppler. A scholar is included among the top collaborators of U. Keppler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Keppler. U. Keppler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Seifart, Ulf, Katrin Jensen, M. Schröder, et al.. (2005). Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer. 48(3). 415–422. 15 indexed citations

Griesinger, Frank, Tobias R. Overbeck, Hilmar Dörge, et al.. (2005). Phase II induction therapy with docetaxel and carboplatin in NSCLC IIIA/IIIB: FDG-PET response predicts overall and disease free survival. Journal of Clinical Oncology. 23(16_suppl). 7184–7184. 2 indexed citations

Scagliotti, Giorgio V., Hedy L. Kindler, Michael J. Vasconcelles, et al.. (2003). Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B₁₂ as Front-Line Therapy in Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 21(8). 1556–1561. 200 indexed citations

Rosell, Rafael, U. Gatzemeier, Daniel Betticher, et al.. (2002). Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology. 13(10). 1539–1549. 219 indexed citations

Korfel, Agnieszka, et al.. (2002). Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. European Journal of Cancer. 38(13). 1724–1729. 92 indexed citations

Scagliotti, Giorgio V., et al.. (2001). Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma. European Journal of Cancer. 37. S20–S21. 20 indexed citations

Gatzemeier, U., R. Rosell, Daniel Betticher, et al.. (1999). Randomized Pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 35. S246–S246. 28 indexed citations

Korfel, Agnieszka, et al.. (1999). Response of symptomatic brain metastases of small cell lung cancer (SCLC) to topotecan also after preceeding whole-brain radiation (WBI). European Journal of Cancer. 35. S251–S251. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact